There are two FDA-approved blood tests that may detect early Alzheimer's disease, but people can only use them when they already have symptoms of memory loss.

The 2026 research finding from researchers at Washington University School of Medicine in St. Louis—if validated in broader populations—suggests that an already available blood test could estimate when Alzheimer's symptoms may begin within a margin of several years. The test detects a protein called p-tau217 found in blood plasma and the researchers incorporated the findings from that blood test into a statistical model to come up with the symptom timeline predictions.

In 2021, an investigation revealed photo manipulation in images from a seminal 2006 paper by researcher Sylvain Lesné on the role of amyloid plaques in progressive Alzheimer's disease. The revelation rocked the field, leaving many wondering whether they had tried to build on fabricated results.

The exact causes of Alzheimer's—and how to treat it—continue to be the subject of intense research. Two leading factors are amyloid beta plaques and tau protein tangles, which effectively pile up in the brain and interfere with neurons and cause cell death, which manifests as memory loss and other symptoms.

Established screening tests for Down syndrome in utero are reliable and accurate. But a New York Times investigation into expanded prenatal genetic tests for very rare diseases—much rarer than Down syndrome—found that more than 80 percent of the positive test results turned out to be wrong based on follow-up testing. These expanded tests for rare diseases are performed from a blood draw at 10 weeks of pregnancy and aim to detect chromosomal abnormalities linked to rare diseases. Companies that offer these controversial tests counter that it's only a screening test—not a diagnosis—picking up true positives and noting that patients can and should be counseled about what the findings mean.

Early-onset Alzheimer’s typically emerges around 40 to 50 years of age, with devastating effects. This video follows Brian, diagnosed with the disease at age 54, as he travels the country as an advocate for research and discusses the progressive mental fog of Alzheimer’s.

Surveys suggest our fear of Alzheimer's as a disease outranks that of heart disease and cancer. This piece argues our fear of aging and the slipping away of our mental capacities make it more difficult to treat Alzheimer's compassionately.

Recent DNA sequencing and molecular biology studies suggest that similarities in genes, neural circuitry and patterns of disease warrant further exploration to potentially better understand both conditions and how to treat them.

The UK's National Health Service has launched a trial for a blood test that can detect a dozen types of cancers with just ten drops of blood. An AI tool looks for genetic material known to be released by tumors, allowing for cancer detection before tumors are large enough to be imaged.

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain.

The US Food and Drug Administration regulates supplements like foods and can only take action about a supplement if they learn that there are problems with it after it's on the market. This website allows consumers, industry, and others to file a complaint about a product that made them ill or raised other concerns.

Scientists have successfully implanted false memories in mice after studying how the editing process works in the brain. Beyond potentially deleting memories in those with PTSD, upcoming research may allow clinicians to forecast the onset of neurodegenerative diseases.

Certain gene variants can affect how quickly or slowly medications are broken down in the body, affecting drug effectiveness and the risk of drugs failing. Such testing is often not covered by insurance companies though research indicates if these tests were performed for more than six drugs across the US population, avoided ailments would likely climb into the hundreds of thousands.

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval.

Despite more than 100,000 people with Alzheimer's dying each year, the specific cause of death is not the disease itself. Often, secondary diseases arise from complications with the disease, including pneumonia, severe falls, malnutrition, or infection. Read more about the range of complications caused by Alzheimer's here.

Read this primer about Alzheimer's disease and learn what factors increase the risk of this form of dementia, including genetics, being a woman, and health conditions, including high blood pressure.

An analysis of existing GLP-1 research, published in April 2025, indicated that GLP-1 drugs reduce inflammation, with numerous health benefits. The work notes that GLP-1s were linked with a statistically significant reduction in dementia in randomized clinical trials.

Odor is more effective than both visual and verbal cues for triggering autobiographical recall in Alzheimer's disease, according to 2021 research.

The agency proposed a new rule in 2023 to make it explicit that these types of tests are devices under existing law and clarify that that the agency could move to regulate them. They finalized a regulatory change in 2024 that added the words "including when the manufacturer of these products is a laboratory" to an existing law, but a federal district court vacated that edit in March 2025—returning the law to as it was before.

A primer on genetic testing, personalized medicine, and the promise of pharmacogenomics–the use of genetics to predict an individual's response to a drug.

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

The group purchases supplements and tests them for accuracy. When it tested 26 popular B vitamin supplements, it found five failed their tests because they provide either significantly less or much more of the ingredients than listed. This type of product-label mismatch can occur because the FDA does not regulate these products as it would a drug.

Known as aging clocks, these tests compare various metrics, like DNA methylation patterns and protein profiles, to healthy baselines. However, the non-uniformity of these baselines across individuals limits testing accuracy and prevents their clinical use.

All the coverage of research into promising (but often unproven) medical treatments involving stem cells has created conditions allowing some people to engage in activities regulators describe as scams. As this news article explains, attorneys general in at least seven states have taken legal action against businesses that promised (costly) stem cell treatments but allegedly engaged in fraud.

The direct-to-consumer genetic test, approved by US regulators in 2018, examines 3 out of the more than 1,000 known breast cancer-linked genetic mutations. It looks for genetic variations that can increase risk for breast, ovarian, and other cancers. These mutations are most commonly found among Jewish people with Eastern European ancestry.